MRK

United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.

SeekingAlpha · 7h ago

Build a disciplined options income strategy targeting 12–15% annually. Read the full analysis here.

SeekingAlpha · 9h ago

In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...

Yahoo · 16h ago

Key Stats for Merck Stock52-Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR): around 4%NTM EV/EBITDA: around 17xLTM Gross Margin: 75. 9%Dividend Yield: 2.

Yahoo · 1d ago

Merck’s stock has had a strong multi year run, and with the shares closing at US$148.78 most recently, the key question for you is whether that level is supported by the cash the business can generate over time. Over the past 5 years, Merck has delivered a total return of 113.0%, which puts real weight on the question of whether the current valuation still lines up with its underlying cash flows. Recent approvals and label expansions for treatments such as Welireg combinations, WINREVAIR and...

Yahoo · 1d ago

TOKYO, September 25, 2026--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn.

Yahoo · 1d ago

Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 3.0% on an annualized basis producing an average annual return of 15.2%. Currently, Merck & Co has a market capitalization of $364.51

Benzinga · 1d ago